National Tunisian Clinical Registry on CardioVascular Secondary Prevention Clinical
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 7,284
- 试验地点
- 1
- 主要终点
- Compliance
研究概览
简要总结
A non-interventional, national longitudinal multicenter study of CV secondary prevention in Tunisia
详细描述
The NATURE-STOP-CHD study is carried out in Tunisia at cardiology consultations in hospitals and in the liberal sector. The study is a longitudinal non-interventional registry of patient undergoing secondary CV prevention. The data collected are managed by the DACIMA Clinical Suite® platform, which complies with international standards: FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPPA (Health Insurance Portability and Accountability Act), ICH (International Conference on Harmonisation), MedDRA (Medical Dictionary for Regulatory Activities). The DACIMA Clinical Suite® platform allows to track the data entered, check for inconsistencies and missing data, and schedule monitoring visits. A Steering Committee is set up to monitor patient inclusions, verify data sources, perform audit trails and prepare the statistical analysis plan for the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years and < 80 years
- •Patients who have been hospitalized for at least one acute coronary event with coronary revascularization, either percutaneous or surgical by coronary artery bypass grafting, or who have confirmed coronary artery disease requiring optimal medical treatment for more than 6 months
- •Coronary event happening in 2024
- •Informed, read and signed consent
排除标准
- •Familial hypercholesterolemia
研究组 & 干预措施
Coronary Event
Patient with any coronary event
结局指标
主要结局
Compliance
时间窗: From enrollment to the end of the follow-up (12 months)
Number of subjects with sufficient adherence to their cardiovascular medication
次要结局
未报告次要终点
